MiNK Therapeutics (NASDAQ:INKT) Stock Rating Lowered by Zacks Research

MiNK Therapeutics (NASDAQ:INKT) was downgraded by Zacks Research from a “strong-buy” rating to a “hold” rating in a report issued on Wednesday,Zacks.com reports.

A number of other research analysts have also recently commented on INKT. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of MiNK Therapeutics in a research report on Monday, May 18th. Wall Street Zen upgraded shares of MiNK Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of MiNK Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 6th. One investment analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $35.00.

MiNK Therapeutics Price Performance

Shares of NASDAQ:INKT opened at $11.00 on Wednesday. The business’s 50 day simple moving average is $11.34 and its 200 day simple moving average is $11.23. MiNK Therapeutics has a 1 year low of $8.48 and a 1 year high of $18.17. The company has a market capitalization of $54.78 million, a P/E ratio of -3.87 and a beta of 0.48.

MiNK Therapeutics (NASDAQ:INKT) last announced its quarterly earnings data on Thursday, August 13th. The company reported ($0.62) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.02). On average, sell-side analysts anticipate that MiNK Therapeutics will post -2.75 EPS for the current fiscal year.

Hedge Funds Weigh In On MiNK Therapeutics

A hedge fund recently raised its stake in MiNK Therapeutics stock. Geode Capital Management LLC lifted its holdings in shares of MiNK Therapeutics, Inc. (NASDAQ:INKT) by 11.3% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 14,247 shares of the company’s stock after buying an additional 1,441 shares during the period. Geode Capital Management LLC owned about 0.30% of MiNK Therapeutics worth $159,000 as of its most recent filing with the SEC. Institutional investors own 2.87% of the company’s stock.

MiNK Therapeutics Company Profile

MiNK Therapeutics, Inc is a clinical-stage biotechnology company developing exosome-based immunotherapies for the treatment of solid tumors. The company’s proprietary platform isolates and engineers naturally occurring extracellular vesicles, or exosomes, to deliver therapeutic payloads—such as mRNA, proteins and modulatory factors—directly into the tumor microenvironment. By leveraging the innate cell‐to‐cell communication properties of exosomes, MiNK aims to reprogram immune cells and overcome immune suppression within solid tumors.

MiNK’s preclinical pipeline features multiple lead candidates designed to repolarize tumor‐associated macrophages and boost T cell–mediated tumor clearance.